《大行报告》花旗上调君实生物(01877.HK)目标价至50元 评级「买入」
花旗在研究报告中指出,君实生物(01877.HK)将与美国药企礼来(Eli Lilly and Company)合作研发及商业化新型冠状病毒中和抗体JS016,并授予礼来大中华地区外独家研发及销售权,相信即将提交中国新药上市申请,并最快於第二季向美国FDA提交申请。
该行认为,在已经使用或可能用於对抗新型冠状病毒各种方法中,中和抗体可能为最理想治疗方法,透过与患者免疫系统部分结合,从而破坏病毒。
花旗调整君实今年至2022年收入及研发开支预测,预期今、明两年净亏损将减少至4.96亿元人民币及1.05亿元人民币,并有望於2022年扭亏,净利润预测由3,400万元人民币调升至5,400万元人民币,维持其「买入」评级,并将目标价由40元上调至50元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.